Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Charles River Laboratories Intl (NY: CRL )

191.68 -1.71 (-0.88%)
Official Closing Price Updated: 4:10 PM EDT, Oct 3, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 317,201
Open 191.59
Bid (Size) 187.01 (1)
Ask (Size) 201.24 (1)
Prev. Close 193.39
Today's Range 190.59 - 193.01
52wk Range 181.22 - 262.00
Shares Outstanding 50,396,622
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Charles River Unveils Lentivation Platform to Expedite LVV-based Gene Therapy Manufacturing
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Announces Opening of RightSourceSM Laboratory, Supporting Stevenage Biocluster
From Charles River Laboratories International, Inc.
Via Business Wire

Performance

YTD
-12.23%
-12.23%
1 Month
-6.17%
-6.17%
3 Month
-8.14%
-8.14%
6 Month
-4.28%
-4.28%
1 Year
-5.94%
-5.94%

More News

Read More
Charles River Laboratories International, Inc. (NYSE: CRL) Long Term Investor Alert: Investigation of Potential Wrongdoing
Via SBWire
What 5 Analyst Ratings Have To Say About Charles River
Via Benzinga
Why Seelos Therapeutics Shares Are Trading Lower By 31%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Charles River Laboratories to Host Virtual Investor Day
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River and Related Sciences Enter Multi-Program Collaboration to Pursue AI-Enabled Drug Discovery Utilizing Logica
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories to Present at Baird and Morgan Stanley Conferences
From Charles River Laboratories International, Inc.
Via Business Wire
Steer Clear of Outrageously Valued VinFast Stock. 3 EV Stocks to Buy Instead.
Via InvestorPlace
Charles River and PathoQuest Announce Publication of a Head-to-Head Study Validating Proprietary Next Generation Sequencing Viral Safety Assay as a Reliable In Vitro Alternative to Animal Testing Methods
From Charles River Laboratories International, Inc.
Via Business Wire
WeWork's Journey From $47B Valuation To Possible Bankruptcy, Mastercard and Visa Reassess Ties with Binance Card, Hawaiian Electric Accused Of Jeopardizing Investigation Of Maui Wildfires: Today's Top Stories
Via Benzinga
Topics Bankruptcy
Exposures Financial Legal
Endangered Horseshoe Crabs Vital In Medical Research, Charles River Lab Commits To Enhanced Protection
Via Benzinga
Charles River Laboratories Announces Plasmid Manufacturing Collaboration with Fondazione Telethon
From Charles River Laboratories International, Inc.
Via Business Wire
CHARLES RIVER ALERT: Bragar Eagel & Squire, P.C. is Investigating Charles River Laboratories International, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
B of A Securities Maintains Buy Rating for Charles River: Here's What You Need To Know
Via Benzinga
US Stocks Edge Lower; Charles River Earnings Top Estimates
Via Benzinga
Charles River Laboratories Announces Second-Quarter 2023 Results
From Charles River Laboratories International, Inc.
Via Business Wire
Lyft, Disney And 3 Stocks To Watch Heading Into Wednesday
Via Benzinga
Investor Sentiment Declines After Moody's Downgrades Credit Ratings Of Banks
Via Benzinga
Buy Alert: 3 Healthcare Stocks Nearing Super Attractive Entry Points
Via InvestorPlace
Charles River Laboratories Expands Access to AAALAC-Accredited, Turnkey Research Space in Key Markets
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Schedules Second-Quarter 2023 Earnings Release and Conference Call
From Charles River Laboratories International, Inc.
Via Business Wire
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Charles River Laboratories International, Inc. (CRL)
From The Law Offices of Frank R. Cruz
Via Business Wire
CRL FINAL DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Charles River Laboratories International, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important July 18 Deadline in Securities Class Action – CRL
From The Rosen Law Firm PA
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Stem, Disney, Charles River, and Virtu and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.